This page shows the latest Valneva news and features for those working in and with pharma, biotech and healthcare.
Valneva will fund 40% of the remaining shared development costs, compared to 30% in the initial agreement. ... Pfizer will pay Valneva tiered royalties of up to 22% which will be complemented by up to $100m in milestones payable to Valneva based on
The European Medicines Agency (EMA) has accepted Valneva’s marketing authorisation application (MAA) for its COVID-19 vaccine candidate, VLA2001. ... Valneva’s vaccine candidate is currently the only whole virus, inactivated, adjuvanted candidate for
Pfizer and Valneva have announced positive phase 2 paediatric results for their Lyme disease vaccine candidate, VLA15. ... The positive paediatric data marks an important step forward in the ongoing development of VLA15, and we are excited to continue
The European Union intends to purchase up to 60 million doses of Valneva’s its inactivated COVID-19 vaccine VLA2001 by the end of 2023. ... Valneva CEO, Thomas Lingelbach, said the company continued to receive messages from people across the world who
Valneva will seek regulatory approval in the UK and European Union after its COVID-19 vaccine candidate performed well in phase 3 trials. ... Valneva hit the headlines this summer when the UK government cancelled a 1.4bn vaccine contract citing
A booster shot of Valneva/Pfizer’s VLA15 vaccine candidate against tick-borne Lyme disease demonstrates a strong immune response. ... Under the agreement, Valneva will fund 30% of the development costs and, in return, Pfizer will pay tiered royalties
More from news
Approximately 15 fully matching, plus 10 partially matching documents found.
The Vivalis shareholders will own 55 per cent of the new company called Valneva based in Lyon and the Intercell shareholders will obtain a 32 per cent premium for their shares.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Appoints David Lawrence and Wolfgang Bender. Commercial stage biotech Valneva has appointed David Lawrence and Wolfgang Bender, a move that will strengthen the senior management team for future growth.
More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.
Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and...